-
1.发明申请USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME 审中-公开作为生物标记用于预防神经损伤性疾病和治疗的AKT磷酸化的使用公开(公告)号：US20140088017A1
公开(公告)日：2014-03-27
申请号：US14119891
申请日：2012-05-23
Inventor： Eran Ovadia , Irun R. Cohen , Johannes Herkel , Raanan Margalit , Melray Pevsner-Fishcher
IPC: C07K7/06 , G01N33/543
CPC classification number: G01N33/6854 , A61K31/343 , A61K38/08 , A61K38/1808 , A61K38/1825 , A61K38/1833 , A61K38/1841 , A61K38/185 , A61K38/1866 , A61K38/1891 , A61K38/30 , A61K45/06 , C07K7/06 , G01N33/54306 , G01N33/6896 , G01N2800/28 , G01N2800/52 , A61K2300/00
Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
Abstract translation: 本发明涉及包含选自SEQ ID NO：1，SEQ ID NO：2，其类似物和衍生物的氨基酸序列的肽用于治疗神经变性疾病如肌萎缩性侧索硬化（ ALS）。 本发明还提供了评估对本发明的肽的治疗反应性的方法。 此外，本发明涉及使用Akt和磷酸化Akt作为生物标志物的ALS进展的预后。
-
公开(公告)号：US11852634B2
公开(公告)日：2023-12-26
申请号：US17081013
申请日：2020-10-27
Inventor： Eran Ovadia , Irun R. Cohen , Johannes Herkel , Raanan Margalit , Meirav Pevsner-Fischer
IPC: G01N33/68 , A61K38/08 , A61K38/18 , A61K31/343 , A61K38/30 , A61K45/06 , C07K7/06 , G01N33/543
CPC classification number: G01N33/6854 , A61K31/343 , A61K38/08 , A61K38/185 , A61K38/1808 , A61K38/1825 , A61K38/1833 , A61K38/1841 , A61K38/1866 , A61K38/1891 , A61K38/30 , A61K45/06 , C07K7/06 , G01N33/54306 , G01N33/6896 , G01N2800/28 , G01N2800/52
Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
-
3.发明申请Pharmaceutical Composition Comprising Amino-Phenyl-Acetic Acid Octadec-(Z)-9-enyl Ester and Use Thereof for Treating Tumors 审中-公开包含氨基苯基 - 乙酸十八 - （Z）-9-烯基酯的药物组合物及其用于治疗肿瘤的药物组合物公开(公告)号：US20150157588A1
公开(公告)日：2015-06-11
申请号：US14412838
申请日：2013-07-04
Applicant: Yeda Research and Development Co., Ltd.
Inventor： Irun R. Cohen , Meir Shinitzky , Raanan Margalit , Michal Cohen-Sfady , Alexandra Zanin-Zhorov
IPC: A61K31/216
CPC classification number: A61K31/216
Abstract: The present invention relates to the compound amino-phenyl-acetic acid octadec-(Z)-9-enyl ester, an enantiomer thereof or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising it, for use in the treatment of tumors and metastases, and to methods for treating a tumor or metastases comprising administering said compound to a subject in need thereof. The present invention particularly relates to said compound when it is dissolved in an ethanol solution.
Abstract translation: 本发明涉及用于治疗肿瘤和转移的化合物氨基 - 苯基 - 乙酸十八 - （Z）-9-烯酯，其对映异构体或其药学上可接受的盐或包含它的药物组合物， 以及用于治疗肿瘤或转移的方法，包括向有需要的受试者施用所述化合物。 当本发明溶于乙醇溶液时，本发明特别涉及所述化合物。
-
Patent Agency Ranking
公开(公告)号：US10288622B2
公开(公告)日：2019-05-14
申请号：US14883685
申请日：2015-10-15
Inventor： Eran Ovadia , Irun R. Cohen , Johannes Herkel , Raanan Margalit , Meirav Pevsner-Fischer
IPC: G01N33/53 , C12Q1/64 , G01N33/68 , A61K38/08 , A61K38/18 , A61K38/30 , A61K45/06 , A61K31/343 , C07K7/06 , G01N33/543
Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogs and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
-
公开(公告)号：US09217041B2
公开(公告)日：2015-12-22
申请号：US14168024
申请日：2014-01-30
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Irit Sagi , Netta Sela-Paswell , Tamar Danon , Raanan Margalit
IPC: A61K39/395 , A61K39/00 , C07K16/40 , C07K16/44
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/44 , C07K2317/55 , C07K2317/76 , C07K2317/92
Abstract: An antibody is disclosed which comprises an antigen recognition region which comprises six CDR amino acid sequences selected from the group consisting of SEQ ID NOs: 4-15. Uses thereof are also disclosed.
Abstract translation: 公开了包含抗原识别区的抗体，其包含选自SEQ ID NO：4-15的6个CDR氨基酸序列。 还公开了其用途。
-
6.发明申请HSP60 DERIVED PEPTIDES AND PEPTIDE ANALOGS FOR SUPPRESSION AND TREATMENT OF NON-AUTOIMMUNE DIABETES 审中-公开HSP60衍生肽和肽类似物用于抑制和治疗非自发性糖尿病公开(公告)号：US20150018271A1
公开(公告)日：2015-01-15
申请号：US14379758
申请日：2013-02-28
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Irun R. Cohen , Raanan Margalit
CPC classification number: A61K38/17 , A61K38/1709 , A61K45/06 , C07K14/47 , A61K2300/00
Abstract: The present invention provides methods of prevention and treatment of Type 2 diabetes (T2D) using peptides and analogs of heat shock protein 60 (hsp60), and for suppression, prevention and treatment of complications associated with T2D. The invention is exemplified using DiaPep277™, a peptide analog of human hsp60. The invention further relates treatment regimens useful for suppression, prevention or treatment of T2D.
Abstract translation: 本发明提供使用热休克蛋白60（hsp60）的肽和类似物预防和治疗2型糖尿病（T2D）的方法，以及用于抑制，预防和治疗与T2D相关并发症的方法。 使用人hsp60的肽类似物DiaPep277 TM来举例说明本发明。 本发明还涉及可用于抑制，预防或治疗T2D的治疗方案。
-
公开(公告)号：US20150011471A1
公开(公告)日：2015-01-08
申请号：US14379772
申请日：2013-02-28
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Irun R. Cohen , Raanan Margalit
IPC: A61K38/17
CPC classification number: A61K38/1709 , A61K9/0019 , A61K9/0024 , A61K38/164 , A61K47/44
Abstract: The present invention provides compositions for use in the treatment of long-established type 1 diabetes (T1D) using peptides and analogs of heat shock protein 60 (Hsp60). The invention is exemplified using DiaPep277, a peptide analog of human Hsp60, which is shown to induce increase in plasma C-peptide and regeneration of islet beta cells. The invention further relates to regimens useful for treatment of long established T1D in patients having no demonstrable islet beta cell-function.
Abstract translation: 本发明提供了使用热休克蛋白60（Hsp60）的肽和类似物治疗长期存在的1型糖尿病（T1D）的组合物。 使用DiaPep277（人Hsp60的肽类似物）来证明本发明，其显示诱导血浆C肽增加和胰岛β细胞的再生。 本发明还涉及可用于在没有可证实的胰岛β细胞功能的患者中治疗长期建立的T1D的方案。
-
公开(公告)号：US20140141014A1
公开(公告)日：2014-05-22
申请号：US14168024
申请日：2014-01-30
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Irit SAGI , Netta Sela-Paswell , Tamar Danon , Raanan Margalit
IPC: C07K16/40
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/44 , C07K2317/55 , C07K2317/76 , C07K2317/92
Abstract: An antibody is disclosed which comprises an antigen recognition region which comprises six CDR amino acid sequences selected from the group consisting of SEQ ID NOs: 4-15. Uses thereof are also disclosed.
Abstract translation: 公开了包含抗原识别区的抗体，其包含选自SEQ ID NO：4-15的6个CDR氨基酸序列。 还公开了其用途。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.02 seconds)
